Cancer
24
Jun 2020
The Swiss cantons are required to jointly draw up a plan for the provision of highly specialized medical treatments (MHS). Until September 2020, the Conference of Cantonal Health Directors is discussing whether complex gynecological tumors, pediatric oncology, bariatric surgery, highly specialized pediatric surgery, and other areas of care should enter the MHS.
Read more
14
May 2020
The corresponding decision by the (the Federal Joint Committee) of January 16, 2020, was published in the Federal Gazette and came into force on April 9, 2020.
Read more
11
May 2020
On April 27, 2020, the Italian Ministry of Health shared the invitation of the Italian “Alliance against cancer,” which is intended for all the interested companies that wish to participate in the CAR-T research project.
Read more
04
May 2020
The revised EBM (German Uniform Evaluation Standard) catalog came into force on April 1, 2020. MTRC has compiled the selection of the most significant changes.
Read more
23
Apr 2020
The revised EBM (German Uniform Evaluation Standard) comes into force on April 1, 2020. Among others, the amendments made concern the billing of the services within the framework of early detection of cervical cancer. Also, the new fee order item (GOP) for the human papillomaviruses (HPV) genotyping service was added.
Read more
16
Apr 2020
Patients with a newly diagnosed glioblastoma will have an opportunity to benefit from the therapy with tumor-treating fields (TTF) at the expense of statutory health insurance. The Federal Joint Committee (G-BA) decided on March 20, 2020, the details concerning the indications and the quality assurance measures that will apply when prescribing this outpatient treatment method.
Read more
27
Mar 2020
In March 2020, Swedish Skåne Region has released a report for the use of hydrogel spacer in radiotherapy of prostate cancer. Treatment with hydrogel spacer provides long-term improved quality of life, but the scientific base is limited. The scientific evidence base on the positive effect of the spacer in erectile function is insufficient.
Read more
20
Mar 2020
At the beginning of 2020, the Galician Scientific and Technical Advice Unit released a health technology assessment on the treatment of benign thyroid nodules (TNs) by thermal laser or radiofrequency ablation that aimed to assess its safety and clinical effectiveness compared to standard treatment. The methods were considered safe and effective procedures for the treatment of benign, solid, and symptomatic TNs.
Read more
16
Mar 2020
At the beginning of 2020, the Galician Scientific and Technical Advice Unit released a health technology assessment on irreversible electroporation (IRE) for the treatment of liver and pancreatic cancer that aimed to analyze its safety, effectiveness, considerations for use, and the economic, organizational, social, ethical, or legal aspects. The efficacy evidence of IRE in achieving complete ablation is insufficient. Safety evidence is also insufficient as it is unclear whether IRE is safer as the standard treatment.
Read more
04
Mar 2020
In Norway, the mini-HTA for Localizer™ wire-free guidance system designed to mark and guide to non-palpable breast lesions was released at the end of January 2020. The method was determined as efficient and safe. It was recommended to be introduced as part of the clinical routine in the hospital.
Read more
03
Feb 2020
The HTA unit of the Lombardy region opens the possibility for the public to comment on the health technologies which are in the assessment phase. The call is open until February 28, 2020.
Read more
The costs for biomarker-based breast cancer testing covered by statutory health insurance in Germany
30
Jan 2020
From January 2020, the "Oncotype DX Breast Recurrence Score" test is reimbursed by the health insurance companies at an extra budget of 3,296.50€. This is explicitly the only test that the Federal Joint Committee (G-BA) has included in the contracted medical care.
Read more